ReviewACS chemical neuroscience2025
Can Oxytocin Neuropeptide Promote Human Mesenchymal Stem Cells to Neuron Conversion?: A Novel Approach in Future Neurotherapeutic Research.
Review in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exercise-induced neuropeptidergic and neurochemical neuroadaptation in stress regulation and emotional disorders.Acta neurologica Belgica · 2026Review
- "Primed for Repair: Harnessing Hypoxia, Mechanobiology, and Gene Editing to Enhance MSC Potency and Clinical Translation".Stem cell reviews and reports · 2026Review
- Cell-Penetrating Peptoids: A Dual Functional Strategy for Upcoming Neuroregeneration Application.ACS chemical neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases are characterized by progressive neuronal loss, for which human mesenchymal stem cell (hMSC)-based therapies present a promising regenerative approach. Oxytocin, a neuropeptide known for its neuroprotective and anti-inflammatory properties, has been reported to inhibit GSK-3β in certain models. Given the established role of GSK-3β inhibition in promoting neurogenesis via Wnt/β-catenin signaling, this viewpoint explores the hypothesis that oxytocin could serve as a peptide-based cue to drive neuronal differentiation of MSCs. Consequently, developing effective therapy by emulating the oxytocin sequence could substantially enhance neuroregenerative treatments in neuroregenerative research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.